These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 28673587)

  • 41. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical effectiveness of exenatide in diabetic patients waiting for bariatric surgery.
    Iglesias P; Civantos S; Vega B; Pavón I; Guijarro G; Monereo S
    Obes Surg; 2015 Mar; 25(3):575-8. PubMed ID: 25589020
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C
    Neuropharmacology; 2018 Jul; 136(Pt B):251-259. PubMed ID: 29402504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diabetes remission following metabolic surgery: is GLP-1 the culprit?
    Vidal J; Jiménez A
    Curr Atheroscler Rep; 2013 Oct; 15(10):357. PubMed ID: 23955665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Roux-en-Y gastric bypass versus calorie restriction: support for surgery per se as the direct contributor to altered responses of insulin and incretins to a mixed meal.
    Berggren J; Lindqvist A; Hedenbro J; Groop L; Wierup N
    Surg Obes Relat Dis; 2017 Feb; 13(2):234-242. PubMed ID: 27894746
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism.
    Lutz TA; Osto E
    Curr Opin Lipidol; 2016 Jun; 27(3):257-63. PubMed ID: 27031273
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postprandial GLP-1 Secretion After Bariatric Surgery in Three Cases of Severe Obesity Related to Craniopharyngiomas.
    Bretault M; Laroche S; Lacorte JM; Barsamian C; Polak M; Raffin-Sanson ML; Touraine P; Bouillot JL; Czernichow S; Carette C
    Obes Surg; 2016 May; 26(5):1133-7. PubMed ID: 26922186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity.
    Nolen-Doerr E; Stockman MC; Rizo I
    Curr Obes Rep; 2019 Sep; 8(3):284-291. PubMed ID: 31124035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Mar; 18(3):224-35. PubMed ID: 26500045
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus.
    Vetter ML; Cardillo S; Rickels MR; Iqbal N
    Ann Intern Med; 2009 Jan; 150(2):94-103. PubMed ID: 19153412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery.
    Timmermans M; Topal B; Sanches EE; DE Jongh FW; Cagiltay E; Celik A; Ribeiro R; Parmar C; Ugale S; Proczko M; Stepaniak PS; Buise MP; Severin R; Pouwels S
    Minerva Endocrinol (Torino); 2022 Dec; 47(4):449-459. PubMed ID: 33759444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beneficial Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients with Type 2 Diabetes Mellitus: Analysis of Responders and Non-Responders.
    Stratmann B; Krepak Y; Schiffer E; Jarick I; Hauber M; Lee-Barkey YH; Fischer M; Tschoepe D
    Horm Metab Res; 2016 Sep; 48(10):630-637. PubMed ID: 27589345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relevance of weight in the management of patients with type 2 diabetes mellitus: towards an adipocentric approach to diabetes.
    Gorgojo Martínez JJ
    Med Clin (Barc); 2016 Nov; 147 Suppl 1():8-16. PubMed ID: 28760227
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measurement of Gastrointestinal Hormones.
    Albrechtsen NJW
    Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Duodenal-jejunal bypass improves diabetes and liver steatosis via enhanced glucagon-like peptide-1 elicited by bile acids.
    Kashihara H; Shimada M; Kurita N; Sato H; Yoshikawa K; Higashijima J; Chikakiyo M; Nishi M; Takasu C
    J Gastroenterol Hepatol; 2015 Feb; 30(2):308-15. PubMed ID: 25088988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Metabolic effects of bariatric surgery].
    Winkler G
    Orv Hetil; 2013 Jan; 154(1):3-9. PubMed ID: 23274228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.